Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
activities of daily living
activities of daily living scale
adverse drug reaction
agitation
akathisia
alpha methyldopa hydrazine
Alzheimer's disease
amiodarone
amphotericin B
anticholinergic drugs
anticonvulsants
anticonvulsants, cognitive function with
anticonvulsants, untoward effects of
antidepressant
anxiolytic agents
asterixis
ataxia
ataxia, cerebellar
ataxia, truncal
ataxic gait
autonomic dysfunction
basal ganglia
basal ganglia, lesion of
benign essential tremor
bethanechol
bradykinesia
brain transplantation
burning paresthesia
buspirone
butyrophenone
calcium antagonist
calcium antagonist, side effects of
CAT scan
CAT scan, abnormal
CAT scan, contrast enhanced
CAT scan, emission
CAT scan, emission, abnormal
central nervous system, infection of
cerebrospinal fluid, MHPG(3-methoxy 4-hydroxyphenyl glycol)
cerebrovascular accident
cerebrovascular accident, acute management of
chemotherapy, CNS treatment and complications with
chlorpromazine
cholinergic drug
chorea
cinnarizine
clozapine
cognition
complications
contrast agents, neurotoxicity of
creatine phosphokinase(CPK)elevated
cyanide poison
dementia
depression
diltiazem
diplopia
diquat
disulfiram
dopamine antagonist
drug abuse
drug abuse, neurologic complications of
drug induced neurologic disorders
drug interactions
drug overdose
dyskinesia
dyskinesia, buccal lingual facial
dystonia
dystonia, drug induced
dystonic reaction, acute
ecstasy
emergencies, neurologic
emergency room
encephalopathy
enzyme inhibition
epidemiology of neurology
facial movement disorder
falling
fetal tissue
fever
flunarizine
fluorouracil
fluoxetine
fluvoxamine
GM1 ganglioside
haloperidol
headache
headache, treatment of
hemiballismus
hemichorea
herbicide
hexane
HMGcoA reductase inhibitors
huffing
human immunodeficiency virus type 1
Huntington's chorea
hyperthermia
iatrogenic neurologic disorders
inclusion bodies, eosinophilic cytoplasmic
intellectual deficit
L-dopa
L-dopa, potentiators of
lenticular nucleus, lesion of
lenticular nucleus, lesion of, bilateral
Lewy body
Lewy body disease, diffuse
lipid lowering agent
lithium
locus ceruleus, lesion of
lovastatin
manganese intoxication
medical-legal aspects of neurology
memory, impairment of
mental status, abnormal
meperidine
metoclopramide
migraine, prophylaxis
migraine, treatment of
misdiagnosis
mortality
movement disorder
movement disorder, drug induced
movement disorder, extrapyramidal
movement disorder, treatment of
MPTP
MRI
MRI, abnormal
multiple system atrophy
myoclonus
naproxen
neuroleptic
neuroleptic malignant syndrome
neuroleptic, atypical
neuropathology
neuropathology, brain
neuroprotective agents
neurotoxic
neurotoxin
nonsteroidal anti-inflammatory drug
nursing home
nystagmus
occupational neurologic disorders
octreotide
olanzapine
old age, neurology of
ophthalmoplegia
paresthesias
paresthesias, facial
Parkinson disease
Parkinson disease, arteriosclerotic
Parkinson disease, diagnosis
Parkinson disease, differential diagnosis of
Parkinson disease, drug induced
Parkinson disease, exacerbation
Parkinson disease, misdiagnosis
Parkinson disease, progression
Parkinson disease, surgical treatment of
Parkinson disease, treatment of
Parkinson disease, unmasked
Parkinsonism hyperpyrexia syndrome
Parkinsonism multiple-system atrophy
Parkinsonism syndrome
paroxetine
paroxysmal nonkinesigenic dyskinesia
phenothiazine
poison, neurologic problems with
prognosis
progressive supranuclear palsy
psychiatric disorder
psychiatric problems in neurologic disorders
psychosis
putamen, lesion of
putamen, lesion of, bilateral
quetiapine
Rabbit syndrome
renal failure
review article
rhabdomyolysis
rigidity
risperidone
seizure
seizure, treatment of
selective serotonin reuptake inhibitors
serotonin syndrome
sertraline
sinemet
single photon emission computed tomography
sodium valproate
sodium valproate, toxicity
solvent
stridor
subarachnoid hemorrhage
subarachnoid hemorrhage, treatment of
substantia nigra tissue
tardive dyskinesia
tardive dyskinesia, treatment of
tardive dystonia
tetrabenazine
tic
toxins, nervous system
transient neurologic deficit
treatment of neurologic disorder
tremor
tremor, jaw
tricyclic antidepressant
vasospasm, cerebral
verapamil
vision, blurred
wheelchair
Showing articles 900 to 950 of 1606 << Previous Next >>

The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994

Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994

Movement Disorders Following Lesions of the Thalamus or Subthalamic Region
Mov Disord 9:493-507, Lee,M.S. &Marsden, C.D., 1994

Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993

Prolactin-Secreting Macroadenomas in Adolescents, Response to Bromocriptine Therapy
Am J Dis Child 147:1057-1061, Tyson,D.,et al, 1993

Autosomal Dominant Parkinsoniam with Benign Course and Typical Lewy-Body Pathology
Neurol 43:2222-2227, Golbe,L.I.,et al, 1993

Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993

Fatigue in Parkinson's Disease
Neurol 43:2016-2018, Friedman,J.&Friedman,H., 1993

Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993

Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993

The Motor Disorder of Multiple System Atrophy
JNNP 56:1239-1242, Quinn,N.P.&Marsden,C.D., 1993

Thalamic Stimulation & Prox Tremor, A Specific Target in Nucleus Ventrointermedius Thalamik
Arch Neurol 50:498-500, Nguyen,J-P.&Degos,J-D., 1993

Reflex Anoxic Seizures
BMJ 307:214-215, Appleton,R.E., 1993

Functional Integration of Cortical Grafts Placed in Brain Infarcts of Rats
Ann Neurol 34:362-368, Grabowski,M.,et al, 1993

Transplants for Stroke Patients
Ann Neurol 34:322-323, Sharp,F.R., 1993

Subcortical Dementia
BMJ 307:1-2, Dunne,F.J., 1993

Juvenile Myoclonic Epilepsy
Arch Neurol 50:594-598, Grunewald,R.A.&Panayiotopoulos,C.P., 1993

Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993

Coital Cerebral Hemorrhage
Neurol 43:2683-2685, Finelli,P.F., 1993

Clinicopath Conf
progressive Supranuclear Palsy, Case 46-1993, NEJM 329:1560-1567993., , 1993

Prognostic Significance of the Onset Mode in Parkinsonism
Neurol 43:829-830, Rajput,A.H.,et al, 1993

PET Imaging of the Dopamine Transporter with 11C-WIN 35, 428 Reveals Marked Declines in Mild Parkinson's Disease
Ann Neurol 34:423-431, Frost,J.J.,et al, 1993

Levodopa Improves Spatial Contrast Sensitivity in Parkinson's Disease
Arch Neurol 50:721-724, Hutton,J.T.,et al, 1993

T2 Relaxation Time in Patients with Parkinson's Disease
Neurol 43:697-700, Antonini,A.,et al, 1993

The Spectrum of Levodopa-Related Fluctuations in Parkinson's Disease
Neurol 43:1459-1464, Riley,D.E.&Lang,A.E., 1993

Blood Levodopa Levels and Unified Parkinson's Disease Rating Scale Function:With and Without Exercise
Neurol 43:1040-1042, Goetz,C.G.,et al, 1993

Mitochondrial Involvement in Parkinson's Disease:The Controversy Continues
Neurol 43:2170-2172, DiMauro,S., 1993

Patent Foramen Ovale:Is Stroke Due to Paradoxical Embolism?
Stroke 24:31-34, Ranoux,D.,et al, 1993

Dopaminergic Treatment of Restless Legs and Rebound Phenomenon
Neurol 43:455, Guilleminault,C.,et al, 1993

Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993

A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993

Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993

Movement Disorders with Cerebral Toxoplasmosis and AIDS
Movement Disorders 8:107-112, Nath,A.,et al, 1993

Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993

Comparisons of Therapeutic Effects of Levodopa
Levodopa & Selegiline, & Bromocriptine in Pts with Early, Mild Parkinson's, Parkinson's Res Grp in U, , BMJ 372,1993., 1993

Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993

Comparison of Striatal 18F-dopa Uptake in Adult-Onset Dystonia-Parkinsonism, Parkinson's & Dopa-Responsive Dystonia
Neurol 43:1563-1568, Turjanski,N.,et al, 1993

Identical Twins with Similar Onset of Parkinson's Disease:A Case Report
Neurol 43:1159-1161, Pahwa,R.,et al, 1993

Parkinson's Disease:A Test of the Multifactorial Etiologic Hypothesis
Neurol 43:1173-1180, Semchuk,K.M.,et al, 1993

Environmental Causation of Parkinson's Disease
Arch Neurol 50:651-652, Rajput,A.H., 1993

The Nonenvironmental Basis for Rising Mortality from Parkinson's Disease
Arch Neurol 50:653-656, Riggs,J.E., 1993

Risk Factors for Parkinson's Disease
Neurol 43:1693-1697, 16411993., Hubble,J.P.,et al, 1993

Environmental Antecedents of Young-Onset Parkinson's Disease
Neurol 43:1150-1158, Butterfield,P.G.,et al, 1993

Olfactory Testing Differentiates Between Progressive Supranuclear Palsy & Idiopathic Parkinson's Dis
Neurol 43:962-965, Doty,R.L.,et al, 1993

Defecatory Function in Parkinson's Disease:Response to Apomorphine
Ann Neurol 33:490-493, Edwards,L.L.,et al, 1993

Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993

Faithful Fashion:Survival Status of the Brain Transplant Cure for Parkinsonism
Neurol 43:644-649, Landau,W.M., 1993

Practice Parameters:Initial Therapy of Parkinson's Disease
Report of the Quality Standards Subcommittee of AAN, Neurol 43:1296-12971993., , 1993

Clinical Experience with Controlled-Release Carbidopa/Levodopa in Parkinson's Disease
Neurol 43:677-681, Pahwa,R.,et al, 1993

Aspartame Use in Parkinson's Disease
Neurol 43:611-613, Karstaedt,P.J.&Pincus,J.H., 1993



Showing articles 900 to 950 of 1606 << Previous Next >>